The round positions Semma to start learning whether its insulin-producing cells can control blood sugar levels in Type 1 diabetics.
Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.
When payers and biopharma fight over pricing, patients with rare diseases can suffer. See how Real World Evidence and value-based contracts can help.
The series C, which moves Codiak’s total haul up toward $170 million, tees the biotech up to move its lead candidate into clinical trials.
The series A positions the startup, Mavupharma, to further its work on the use of oral STING modulators to treat cancer and infectious diseases.
AstraZeneca doubles down on Chinese business through a new drug development joint venture with a state-backed private equity firm.
The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.
The series B equips X4 to move deeper into the clinic on two fronts, with phase 2 and 3 trials in cancers and rare diseases on the horizon.
Using tech licensed from Yale University, Inozyme Pharma has emerged from stealth with $49 million and a mission.
Locus Biosciences is moving ahead with a first clinical trial for its CRISPR-based antimicrobial drugs—armed with $19 million in series A funding.
Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer.